Nephro Care India (NSE:NEPHROCARE) Piotroski F-Score: 5 (As of Sep. 21, 2026) — 29% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:NEPHROCARE Nephro Care India Ltd NSE:NEPHROCARE
48 GF Score
Price ₹93.75
! 2 Warning Signs
View Full Analysis

What is Nephro Care India Piotroski F-Score?

Nephro Care India NSE:NEPHROCARE +2.29% 48 Piotroski F-Score is 5 as of Sep. 21, 2026, which is 29% below its 10-year median of 7.00. GuruFocus rates NSE:NEPHROCARE with a GF Score™ of 48/100. The stock has 2 warning signs investors should review. Among 651 Healthcare Providers & Services companies, Nephro Care India ranks better than 56.07% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Nephro Care India has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Nephro Care India's Piotroski F-Score or its related term are showing as below:

NSE:NEPHROCARE' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 7   Max: 9
Current: 5

During the past 6 years, the highest Piotroski F-Score of Nephro Care India was 9. The lowest was 5. And the median was 7.

Nephro Care India  (NSE:NEPHROCARE) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Nephro Care India Piotroski F-Score Related Terms


Nephro Care India Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Nephro Care India's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nephro Care India Piotroski F-Score Chart

Nephro Care India Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial N/A 9.00 6.00 7.00 5.00

Nephro Care India Semi-Annual Data
Mar21 Mar22 Mar23 Dec23 Mar24 Sep24 Mar25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 7.00 0.00 0.00 5.00

NSE:NEPHROCARE vs HCA, THC, EHC: Piotroski F-Score Comparison

For the Medical Care Facilities subindustry, Nephro Care India's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nephro Care India Piotroski F-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Nephro Care India's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Nephro Care India's Piotroski F-Score falls into.


NSE:NEPHROCARE
48GF Score
Nephro Care India Ltd NSE:NEPHROCARE
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹33.7 Mil.
Cash Flow from Operations was ₹22.1 Mil.
Revenue was ₹847.1 Mil.
Gross Profit was ₹583.4 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (682.845 + 727.209) / 2 = ₹705.027 Mil.
Total Assets at the begining of this year (Mar25) was ₹682.8 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0.0 Mil.
Total Current Assets was ₹307.9 Mil.
Total Current Liabilities was ₹152.8 Mil.
Net Income was ₹36.4 Mil.

Revenue was ₹460.3 Mil.
Gross Profit was ₹269.0 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (209.672 + 682.845) / 2 = ₹446.2585 Mil.
Total Assets at the begining of last year (Mar24) was ₹209.7 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0.0 Mil.
Total Current Assets was ₹282.4 Mil.
Total Current Liabilities was ₹140.3 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Nephro Care India's current Net Income (TTM) was 33.7. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Nephro Care India's current Cash Flow from Operations (TTM) was 22.1. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=33.69/682.845
=0.0493377

ROA (Last Year)=Net Income/Total Assets (Mar24)
=36.389/209.672
=0.17355202

Nephro Care India's return on assets of this year was 0.0493377. Nephro Care India's return on assets of last year was 0.17355202. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Nephro Care India's current Net Income (TTM) was 33.7. Nephro Care India's current Cash Flow from Operations (TTM) was 22.1. ==> 22.1 <= 33.7 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0/705.027
=0

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/446.2585
=0

Nephro Care India's gearing of this year was 0. Nephro Care India's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=307.861/152.753
=2.01541705

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=282.361/140.312
=2.01237955

Nephro Care India's current ratio of this year was 2.01541705. Nephro Care India's current ratio of last year was 2.01237955. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Nephro Care India's number of shares in issue this year was 16.515. Nephro Care India's number of shares in issue last year was 15.281. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=583.369/847.149
=0.6886262

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=269.011/460.31
=0.58441268

Nephro Care India's gross margin of this year was 0.6886262. Nephro Care India's gross margin of last year was 0.58441268. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=847.149/682.845
=1.24061683

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=460.31/209.672
=2.19538136

Nephro Care India's asset turnover of this year was 1.24061683. Nephro Care India's asset turnover of last year was 2.19538136. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+1+1+0+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Nephro Care India has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Nephro Care India (NSE:NEPHROCARE) has a Piotroski F-Score of 5 as of Sep. 21, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Nephro Care India and its competitors. This is 29% below median its historical median of 7.00. Over the past decade, Nephro Care India's Piotroski F-Score has ranged from 5.00 to 9.00. According to the industry distribution chart, Nephro Care India ranks #286 out of 651 companies in the Healthcare Providers & Services industry, placing it in the top 43.9%.
Is Nephro Care India's Piotroski F-Score too high?
Nephro Care India's current Piotroski F-Score of 5 is 29% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 9.00. The Healthcare Providers & Services industry median Piotroski F-Score is 5.00. Nephro Care India's value of 5 is 0% at this industry median. Based on the distribution chart, Nephro Care India ranks #286 out of 651 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Nephro Care India has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Nephro Care India's Piotroski F-Score compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Nephro Care India ranks #286 out of 651 companies for Piotroski F-Score. This puts Nephro Care India in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Nephro Care India's value of 5 is 0% at this benchmark. Historically, Nephro Care India's own Piotroski F-Score has ranged from 5.00 to 9.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Nephro Care India has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Healthcare Providers & Services company?
The median Piotroski F-Score among Healthcare Providers & Services companies is 5.00, based on 651 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nephro Care India's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Nephro Care India and its competitors. For the Healthcare Providers & Services industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nephro Care India's current Piotroski F-Score is 5, which is 29% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nephro Care India stock overvalued right now?
Nephro Care India (NSE:NEPHROCARE) has a current Piotroski F-Score of 5. The current Piotroski F-Score is 5, which is 29% below median its 10-year median of 7.00 and 0% at the Healthcare Providers & Services industry median of 5.00. Nephro Care India's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Nephro Care India (NSE:NEPHROCARE), the current Piotroski F-Score is 5 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nephro Care India Business Description

Address c/o EFC India - Millenium City IT Park, Tower 2, 12th Floor, DN 62, DN Block, Sector V, Bidhannagar, Kolkata, WB, IND, 700091
Nephro Care India Ltd is a Kolkata-based healthcare provider specializing in comprehensive medical services for renal patients. The company serves as a one-stop treatment center, offering a broad spectrum of clinical and lifestyle solutions, along with specialized treatments for renal insufficiency. Its holistic care framework addresses not only the medical and physiological aspects of treatment but also focuses on lifestyle and spiritual wellness, providing an integrated approach to patient care.
48GF Score

Get the complete analysis for NSE:NEPHROCARE

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹93.75
Price